Exploiting signalling pathways involved in CLL to develop novel therapies

Silvia Deaglio

Silvia Deaglio, MD, PhD, from University of Turin, Turin, Italy, discusses current drugs on the market for the treatment of chronic lymphocytic leukemia (CLL), including anti-PD1/PDL1 antibodies and lenalidomide. She adds that there are several signalling pathways involved in CLL progression and these are under intense investigation by both pharmaceutical companies and academic researchers with the aim to develop drugs that could inhibit the tumour microenvironment. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.

Share this video